Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Why this matters
This ethereum story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on CointelegraphRelated market context
Swiss National Bank holds $109.3 million in Strategy shares, a side door to Bitcoin
The SNB's indirect Bitcoin exposure highlights how digital assets are subtly integrating into traditional financial systems despit...
JPMorgan reports 36% rise in Strategy share holdings and $540 million in BlackRock’s bitcoin ETF
JPMorgan reported 224,545 more Strategy shares in the third quarter as its BlackRock bitcoin ETF holdings climbed to 11.4 million...
MSCI Cuts Strategy From Global Indexes, Putting Bitcoin Treasury Model Under Pressure
Key Takeaways: Under new classification rules instituted by MSCI, Strategy will be phased out of the global equity index. The chan...
JPMorgan Buys More Strategy and Bitcoin ETF Despite MSCI Saylor Blow
JPMorgan is quietly increasing its Bitcoin exposure while the crypto market is being beaten up. The banking giant raised its Strat...
Kraken Parent Payward Swaps Its Headline Metric, Reports $487 Million in Q3 Platform Margin
Payward, the privately held parent of Kraken, publishes selected quarterly figures rather than SEC filings, and until now led them...
DOJ, CFTC Sue Arkansas to Block Kalshi Crackdown as Prediction Market Battle Escalates
The U.S. Department of Justice and Commodity Futures Trading Commission (CFTC) have filed a federal lawsuit against Arkansas, seek...